Company Overview and News
OncoSil Medical Ltd (ASX:OSL) has received strong shareholder support for its share purchase plan, with applications materially exceeding the aggregate capped amount of $4 million at 12 cents per share.
OncoSil Medical Ltd (ASX:OSL) is viewed by analysts at Bell Potter as substantially undervalued based on Tuesday’s closing price of 13 cents.
OncoSil Medical Ltd’s (ASX:OSL) pancreatic cancer clinical study has demonstrated significant local disease control with up to 73% reduction in tumour volume observed 4 weeks post implant.
OncoSil Medical Ltd (ASX:OSL) continues to make progress, having recruited 28 subjects into the study group of its Global Pancreatic Cancer Clinical Study Program, up from 23 patients on 22 September.
OncoSil Medical Ltd (ASX:OSL) continues to make steady progress, having recruited 23 subjects into the study group of its Global Pancreatic Cancer Clinical Study Programme.
OncoSil Medical (ASX:OSL) has received approval from the Institutional Review Board (IRB) of the MD Anderson Cancer Center at the University of Texas for its global clinical study program in pancreatic cancer. The approval is the final step for US hospitals to agree to participate in a clinical study and recruit and treat patients under the agreed study protocols. MD Anderson will now finalise site initiation and complete final training before first patient recruitment which is anticipated to occur in May.
Oncosil Medical (ASX:OSL) has received a Buy Recommendation and a price target of $0.38 per share from broker Wilsons.
OncoSil Medical (ASX:OSL) and Monash Health has recruited the first subject for a global clinical study program of OncoSil™ device in pancreatic cancer.
OncoSil™ is a targeted radioactive isotope (Phosphorous-32), implanted directly into a patient’s pancreatic tumours via an endoscopic ultrasound.
- Johns Hopkins Hospital and MD Anderson Cancer Centre are the leading U.S. centres; - Investigational Review Board (IRB) process has commenced and is on-going for these two U.S. centres; - Guy’s and St Thomas’ Hospitals, London are the leading UK centres; and - Monash Health has agreed to be the lead Australian centre – ethics submission filed and under review.
The OncoPac-1 study is set to commence recruitment in 1Q CY17 at 10 prestigious oncology centres around the world, headlined by MD Anderson (Texas) and Johns Hopkins (Baltimore).
OncoSil is a late stage medical devices company focused on localised treatments for patients with pancreatic and liver cancer.
OncoSil Medical Ltd (ASX:OSL) has received a Buy rating and $0.42 per share price target from Wilsons Research.
OncoSil Medical Ltd (ASX:OSL) is developing safer and more effective ways to deliver radiation therapy to cancer patient’s tumours. The current product in development, OncoSil™, is a locally implanted medical device that emits radiation into pancreatic tumours for up to three months.
High Arctic Energy Services Inc. more than tripled earnings estimates of .04 per share, by posting .13 per share.
16h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
16h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...